Disability Progression
Q&A: International Headache Society encourages providers to realign goals of migraine care
The International Headache Society recently issued a position paper that upgraded the standards for migraine prevention, providing a four-pronged framework for reassessing the goals for migraine control and prevention.
Tolebrutinib particularly beneficial in patients with MS who have more MRI lesions
WEST PALM BEACH, Fla. — Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show.
Physical activity lowers risk for disability worsening in multiple sclerosis
WEST PALM BEACH, Fla. — For patients with MS, the risk for disability worsening was reduced with physical activity, highlighting the importance of recommending it in practice, researchers reported at ACTRIMS.
Early initiation of Kesimpta associated with lower rates of disability worsening in MS
Early initiation and continuation of Kesimpta in those with relapsing MS was associated with lower rates of disability worsening up to 6 years compared with those who switched medication, according to a presentation at ECTRIMS 2024.
Tolebrutinib delays onset of MS disability progression in phase 3 trial
An oral brain-penetrant therapeutic delayed the onset of confirmed disability progression compared with placebo in those with non-relapsing secondary progressive MS, according to results from a phase 3 study.
Clemastine fumarate linked to accelerated disability progression in MS
WEST PALM BEACH, Fla. — Treatment with clemastine fumarate was linked to accelerated disease and disability progression due to pyroptosis in a small cohort of individuals with multiple sclerosis, according to a presenter at ACTRIMS 2024.
Machine learning model could assist in treatment of MS
WEST PALM BEACH, Fla. — Application of a machine learning model to databases of patients with multiple sclerosis expanded understanding of disease progression, according to a poster at ACTRIMS 2024.
Relapses reduced by 67% after 72 months with ozanimod in patients with multiple sclerosis
WEST PALM BEACH, Fla. — In an open-label extension, treatment with ozanimod demonstrated sustained efficacy for disease progression in patients with relapsing multiple sclerosis, per research presented at ACTRIMS 2024.
Neurofilament light chain predicted confirmed disability worsening at 1 to 2 years in MS
For those with multiple sclerosis, presence of elevated neurofilament light chain biomarkers was associated with symptom progression that predicted clinical disease worsening within 1 to 2 years, according to research from JAMA Neurology.
COVID-19 linked to increased risk of physical disability progression in MS
In a cohort of individuals with MS, a diagnosis of COVID-19 was linked to an increased risk of disability progression compared with those without, according to a presentation from ECTRIMS 2023.